F-star Announces First Patient Dosed in Phase I Clinical Trial of FS118, a First-in-Class Immuno-oncology Bispecific Antibody

F-star Announces First Patient Dosed in Phase I Clinical Trial of FS118, a First-in-Class Immuno-oncology Bispecific Antibody

May 21, 2018 Lead programme FS118 to be investigated in cancer patients relapsing after PD-1/PD-L1 therapy Clinical validation of F-star’s proprietary Modular Antibody Technology™ platform and bispecific format, mAb²™ CAMBRIDGE, England–(BUSINESS WIRE)–F-star, a clinical-stage biopharmaceutical company developing novel bispecific antibodies,